ERG rearrangement in small cell prostatic and lung cancer

Histopathology

Volumn 56, Issue 7, 2010, Pages 937-943

  Scheble, Veit J ^a   Braun, Martin ^a   Wilbertz, Theresia ^a   Stiedl, Ann Cathrin ^a   Petersen, Karen ^a   Schilling, David ^a   Reischl, Markus ^b   Seitz, Gerhard ^c   Fend, Falko ^a   Kristiansen, Glen ^d   Perner, Sven ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^c Klinikum of the Sozialstiftung Bamberg   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

ERG rearrangement; Lung cancer; Prostatic cancer; Small cell cancer

Indexed keywords

ANDROGEN RECEPTOR; CHROMOGRANIN A; EPITHELIAL MEMBRANE ANTIGEN; KI 67 ANTIGEN; NUCLEOSIDASE; PHOSPHOPROTEIN; PROSTATE SPECIFIC ANTIGEN; SYNAPTOPHYSIN; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR ERG; TUMOR MARKER; ERG PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SMALL CELL PROSTATIC CANCER; ADULT; CHI SQUARE DISTRIBUTION; DIFFERENTIAL DIAGNOSIS; GENETICS; LUNG TUMOR; MALE; PATHOLOGY; PROSTATE TUMOR; SMALL CELL CARCINOMA; TISSUE MICROARRAY;

ADULT; CARCINOMA, SMALL CELL; CHI-SQUARE DISTRIBUTION; DIAGNOSIS, DIFFERENTIAL; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77953200272     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03564.x     Document Type: Article

References (36)

1. Stein ME, Bernstein Z, Abacioglu U et al. Small cell (neuroendocrine) carcinoma of the prostate: etiology, diagnosis, prognosis, and therapeutic implications - a retrospective study of 30 patients from the rare cancer network. Am. J. Med. Sci. 2008 336 478 488.
2. Hansel DE, Nakayama M, Luo J et al. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate 2009 69 603 609.
3. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am. J. Surg. Pathol. 2008 32 65 71.
4. Yao JL, Madeb R, Bourne P et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am. J. Surg. Pathol. 2006 30 705 712.
5. Hagood PG, Johnson FE, Bedrossian CW, Silverberg AB. Small cell carcinoma of the prostate. Cancer 1991 67 1046 1050.
6. Christopher ME, Seftel AD, Sorenson K, Resnick MI. Small cell carcinoma of the genitourinary tract: an immunohistochemical, electron microscopic and clinicopathological study. J. Urol. 1991 146 382 388.
7. Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J. Urol. 1992 147 804 807.
8. Schron DS, Gipson T, Mendelsohn G. The histogenesis of small cell carcinoma of the prostate. An immunohistochemical study. Cancer 1984 53 2478 2480.
9. Wenk RE, Bhagavan BS, Levy R, Miller D, Weisburger W. Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia. Cancer 1977 40 773 778.
10. Spiess PE, Pettaway CA, Vakar-Lopez F et al. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer 2007 110 1729 1737.
11. Yildirim Y, Akcay Y, Ozyilkan O, Celasun B. Prostate small cell carcinoma and skin metastases: a rare entity. Med. Princ. Pract. 2008 17 250 252.
12. Xiao WL, Zhou FT, Feng YY, Li NY. Submandibular area metastasis from prostate small cell carcinoma with neuroendocrine differentiation. J. Craniofac. Surg. 2007 18 1155 1157.
13. Tomlins SA, Bjartell A, Chinnaiyan AM et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur. Urol. 2009 56 275 286.
14. Schmidt F, Scheble V, Mertz K, Perner S, Rubin MA. [Frequent gene fusion in prostate cancer: clinical applications in diagnosis, prognosis and therapy]. Dtsch. Med. Wochenschr. 2009 134 1483 1486.
15. Mertz KD, Setlur SR, Dhanasekaran SM et al. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 2007 9 200 206.
16. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005 310 644 648.
17. Perner S, Demichelis F, Beroukhim R et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006 66 8337 8341.
18. Agoff SN, Lamps LW, Philip AT et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod. Pathol. 2000 13 238 242.
19. Ordonez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am. J. Surg. Pathol. 2000 24 1217 1223.
20. Iljin K, Wolf M, Edgren H et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 2006 66 10242 10246.
21. Mehra R, Tomlins SA, Shen R et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod. Pathol. 2007 20 538 544.
22. Cerveira N, Ribeiro FR, Peixoto A et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006 8 826 832.
23. Clark J, Edwards S, Feber A et al. Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene 2003 22 1247 1252.
24. Nam RK, Sugar L, Yang W et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br. J. Cancer 2007 97 1690 1695.
25. Perner S, Mosquera JM, Demichelis F et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am. J. Surg. Pathol. 2007 31 882 888.
26. Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, Panagopoulos I. Confirmation of the high frequency of the TMPRSS2ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 2006 45 717 719.
27. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 2006 66 8347 8351.
28. Yoshimoto M, Joshua AM, Chilton-Macneill S et al. Three-color FISH analysis of TMPRSS2ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006 8 465 469.
29. Mosquera JM, Mehra R, Regan MM et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin. Cancer Res. 2009 15 4706 4711.
30. Han B, Mehra R, Suleman K et al. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod. Pathol. 2009 22 1176 1185.
31. Attard G, Clark J, Ambroisine L et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008 27 253 263.
32. Laxman B, Morris DS, Yu J et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 2008 68 645 649.
33. Kristiansen G, Pilarsky C, Wissmann C et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166MEMD and CD24 as new prognostic markers for patient survival. J. Pathol. 2005 205 359 376.
34. Kristiansen G, Fritzsche FR, Wassermann K et al. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br. J. Cancer 2008 99 939 948.
35. Hermans KG, Bressers AA, van der Korput HA, Dits NF, Jenster G, Trapman J. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res. 2008 68 3094 3098.
36. Perner S, Hofer MD, Kim R et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum. Pathol. 2007 38 696 701.